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Abstract
Background - Association between the C677T polymorphism of the methylene tetrahydrofolate 
reductase (MTHFR) gene and congenital heart disease (CHD) is contentious.  
Methods and Results - We compared genotypes between CHD cases and controls, and between 
mothers of CHD cases and controls.  We placed our results in context by conducting meta-
analyses of previously published studies.   Among 5,814 cases with primary genotype data and 
10,056 controls, there was no evidence of association between MTHFR C677T genotype and 
CHD risk (OR 0.96 [95% CI 0.87-1.07]).  A random-effects meta-analysis of all studies 
(involving 7,697 cases and 13,125 controls) suggested the presence of association (OR 1.25 
[95% CI 1.03-1.51]; p=0.022), but with substantial heterogeneity among contributing studies 
(I2=64.4%), and evidence of publication bias.  Meta-analysis of large studies only (defined by a 
variance of the log OR less than 0.05), which together contributed 83% of all cases, yielded no 
evidence of association (OR 0.97 [95% CI 0.91-1.03]), without significant heterogeneity (I2=0).  
Moreover, meta-analysis of 1,781 mothers of CHD cases (829 of whom were genotyped in this 
study) and 19,861 controls revealed no evidence of association between maternal C677T 
genotype and risk of CHD in offspring (OR 1.13 [95% CI 0.87-1.47]).  There was no significant 
association between MTHFR genotype and CHD risk in large studies from regions with different 
levels of dietary folate.
Conclusions - The MTHFR C677T polymorphism, which directly influences plasma folate levels, 
is not associated with CHD risk. Publication biases appear to substantially contaminate the 
literature with regard to this genetic association.  
Key words: congenital heart disease, MTHFR, genetic association, folate, Mendelian 
randomization  
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Congenital heart disease (CHD) is the commonest birth defect. It affects around 7/1000 live 
births and is a major cause of childhood morbidity and mortality worldwide. 1 Folic acid has long 
been hypothesized to be protective against CHD, and folate deficiency is suspected to be a CHD 
risk factor, but the evidence remains inconclusive. 2 Several retrospectively conducted 
observational epidemiology studies suggest a beneficial effect of periconceptual folate
supplementation on CHD risk, but retrospective studies of adverse pregnancy outcomes may be
susceptible to recall bias and confounding. 3-6  There is only one previous randomized trial of 
preconceptual folate supplementation and CHD, conducted in Hungary, which suggested a 
potentially substantial effect on CHD risk of a multivitamin supplement containing folic acid.
However, statistical significance was borderline (OR=0.48 [95% CI 0.23-1.03]; p=0.055), in an 
analysis involving only thirty cases of CHD. 7 Given the proven protective effect of folate on 
neural tube defect (NTD), further placebo-controlled trials are ethically precluded. A recent 
Canadian study used the introduction of mandatory folate fortification of grain products in 1998 
as an opportunity to conduct a time trend analysis based on medical reimbursement data in which 
CHD incidence rates prior and subsequent to fortification were compared.  In the six years 
following fortification, CHD incidence rates fell by 36%. 8 However, that study was potentially 
vulnerable to confounding by unmeasured coincident secular trends (for example the 
introduction of fetal echocardiography leading to a higher termination rate for fetuses determined 
to have severe CHD).   
Homozygosity for the thymidine allele (T/T genotype) at the C677T polymorphism 
(dbSNP ID: rs1801133) of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, which 
is observed in about 11% of Caucasians and 1-2% of those of African origin, directly causes
lower levels of plasma folate (and higher levels of plasma homocysteine). The nucleotide 
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substitution of thymidine (T) for cytosine (C) leads to the replacement of the amino acid alanine 
with valine at position 222 of the protein and a reduction in the activity of the MTHFR enzyme
(by about one third per copy of the T allele). 9 The effect of genotype is non-additive, with small 
and inconsistent differences in plasma folate between C/C and C/T individuals, but ~25% lower 
plasma folate in T/T than C/C individuals. 10 Determining the presence or absence of association 
between MTHFR C677T genotypes and CHD risk could confirm or refute a causal association 
between folate and CHD risk, through “Mendelian randomization”, the background of which has
been extensively reviewed. 11 In keeping with this notion, the T/T genotype has been shown to be 
a risk factor for NTD when present either in mothers of affected offspring or the offspring
themselves. 12-14 A number of previous studies have investigated the association between C677T 
genotype and CHD risk, but all were small, and the number of genotyped cases in the literature 
has precluded robust conclusions even when these studies were combined in meta-analyses.  
Here we report findings in 5,814 newly genotyped CHD cases and 10,056 controls, set in context 
of a meta-analysis including a total of 7,698 cases and 13,159 controls. 
Methods 
Ethics Statement:
Collection of the European and Australian populations, and conduct of the genetic investigation, 
was approved by the appropriate ethical committees in the participating institutions. Informed 
consent was obtained from all participants (or from parents, if the patients were children too 
young to themselves consent).  The specimens and associated data from the New York State 
newborn screening program were made anonymous prior to testing. The use of these samples 
was approved by the Institutional Review Board of the New York State Department of Health 
and reviewed by the Office for Human Research Protections at the National Institutes of Health.   
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The investigation was conducted according to the principles of the Declaration of Helsinki. 
Populations studied: 
EU-Caucasian Cohort: Cases of CHD were collected from UK congenital heart disease units in 
Bristol, Leeds, Liverpool, Leicester, Newcastle, Oxford and London, and from centres in 
Amsterdam (Netherlands), Leuven (Belgium), Erlangen (Germany), and Sydney (Australia).  All 
cases were of European Caucasian ancestry.  Patients with known genetic causes of CHD (for 
example, Down’s syndrome, 22q11 deletion syndrome, Noonan’s syndrome), or known in utero
teratogen exposure were excluded from analysis. We did not include families in whom CHD 
appeared to be segregating as a Mendelian trait.  Since any effect of MTHFR genotype on risk of 
CHD could be mediated by the early in utero environment, which might well be determined 
chiefly by the mother’s MTHFR genotype, we also collected, where possible, mothers of cases. 
Publicly available genotypes for 3,800 healthy Caucasian individuals at MTHFR C677T 
(rs1801133) were obtained from the Wellcome Trust Case-Control Consortium (WTCCC2) 
common control panel (http://www.wtccc.org.uk).   Additionally, we included 368 healthy 
European Caucasian controls free of CHD ascertained as previously described who were 
genotyped on both platforms employed in this cohort (see below). 15
New York Cohort: This was a population-based, nested case–control study that included all cases 
born in the State of New York with a CHD during 1997 and 1998. Cases were identified using 
the New York State Congenital Malformations Registry. In New York, physicians and hospitals 
are mandated by law to report birth defect cases that come to their attention if the child is under 2 
years of age and was born, or resides, in New York State. Cases were selected if they were listed 
as having a CHD using a modified version of the British Paediatric Cardiac Association code 
system. Cases with chromosomal abnormalities or other malformations in addition to CHDs 
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were excluded.  Controls born in the same interval but free of CHDs were matched to cases on 
race/ethnicity and sex. Two controls were selected for each case.  Information extracted from the 
Congenital Malformations Registry was linked to the records of the New York State Newborn 
Screening Program for retrieval of archived residual dried blood spots. DNA was available on 
>80% of cases listed in the Registry.
Genotyping: 
In the EU-Caucasian cohort, MTHFR C677T (rs1801133) was genotyped either on an Applied 
Biosystems 7900HT Fast Real-Time PCR System (TaqMan) using Sequence Detection System 
v.2.3, or using the Illumina 660W-Quad array which features rs1801133.  Genotypes in the 
WTCCC2 panel of controls were assigned using gene-chip technology.  To rule out any 
systematic error from the use of different platforms, 368 additional healthy controls were 
genotyped using both methodologies to ensure comparability of genotypes between platforms – 
no discrepancies were observed between TaqMan and array derived genotypes.  In the NY 
cohort, MTHFR C677T (rs1801133) was genotyped by detection of allele-specific primer 
extension using matrix-assisted laser desorption/ionization – time of flight (MALDI-TOF) mass 
spectrometry (Sequenom, San Diego, CA, USA). In both cohorts, at least 10% of samples were 
randomly plated a second time and re-genotyped. The concordance rate between these replicates 
was >95%.
Literature search:
The methods for the literature search are described in the Supplementary Information online. 
Statistical analysis:
In the principal analyses, we estimated odds ratios (ORs) for CHD risk with T/T genotype 
compared to (C/T + C/C) genotypes, and their 95% confidence intervals, using logistic  
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regression, for each study.  In subsidiary analyses, chiefly to facilitate comparison of our results 
with previous meta-analyses, we considered the allelic model (where C/T genotype would confer 
intermediate risk between T/T and C/C genotypes); and we also compared T/T with C/C 
genotypes without consideration of C/T heterozygotes. We considered offspring genotypes and 
maternal genotypes in separate analyses.  We decided a priori to calculate pooled OR’s and 95% 
CIs using the DerSimonian and Laird random-effect model, as we anticipated substantial 
heterogeneity between the studies, possibly related to inter-population variability in folate intake 
or to the previously described heterogeneity in C677T genotype frequencies between different 
populations. In subsidiary analyses, we used the Mantel-Haenszel method to calculate fixed-
effects ORs.  We assessed between-study heterogeneity using Cochran’s Q, and also quantified 
heterogeneity using the I2 statistic, which describes the percentage of variation across studies that 
is due to heterogeneity rather than chance. 16 Values of I2 of 25%, 50% and 75% are typically 
considered to indicate low, moderate or high levels of heterogeneity. Publication bias was 
assessed visually using funnel plots of log(OR) against standard error of the OR, and formally 
tested using Egger’s and Begg’s tests.   To address the possibility that particular CHD 
phenotypes might be differentially susceptible to any effect of MTHFR C677T genotype, we 
carried out subgroup analyses among the patients in whom we had primary genotype data in 
three diagnostic subgroups: septal defects (ASD, VSD and AVSD); conotruncal lesions (chiefly 
tetralogy of Fallot, pulmonary stenosis with VSD, pulmonary atresia, and transposition of the 
great arteries); and left-sided lesions (chiefly coarctation of the aorta, aortic stenosis, aortic 
atresia, patent ductus arteriosus and left heart hypoplasia).  Within these groups, if multiple 
lesions were present, patients were assigned based on their clinically dominant defect.  Cases 
who could not be classified into one of these three groups were designated “Other” – examples 
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of defects so classified would include laterality defects and anomalous drainage of the 
pulmonary veins.  In the subgroup analyses, cases were compared with randomly selected 
individuals from the control population, in the ratio of 2 controls per case in each subgroup.  To 
make some allowance for multiple testing, we calculated 99% (rather than 95%) confidence 
intervals for the odds ratios in these subgroup analyses (ie. imposed a significance threshold of 
0.01 rather than 0.05). 
We explored sources of heterogeneity, in particular examining the importance of study 
size, using two statistical approaches.  First, we used the “trim and fill” method, which assumes 
funnel plot symmetry, to estimate and model the studies missing from the analysis due to 
publication bias; and second, we used the selection model of Copas, which assumes a 
relationship between publication probability and the standard error of the estimated OR. 17 We 
examined whether there was a relationship between any risk of CHD associated with TT 
genotype and folate status in low, medium and high folate groups of studies, using meta-
regression; we also calculated the heterogeneity between studies within each of the three groups.
All p-values were two-tailed, and other than in the subgroup analyses p<0.05 was accepted as the 
threshold for significance. Analyses were performed using STATA (Version 10, Stata 
Corporation, College Station, TX, USA).   
Results
Primary genotyping data:  
MTHFR genotypes were successfully assigned in over 95% of participants.  A total of 5,814 
CHD cases and 10,056 controls in the combined EU-Caucasian and NY cohorts had MTHFR
C677T genotype available.  Of these, 4,495 cases (77%) were of Caucasian ethnicity.  The allele 
frequencies corresponded closely with those observed in previous large studies of this 
 at Universitaet Zuerich on January 16, 2014http://circgenetics.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCGENETICS.113.000191
9
polymorphism.  Previously reported differences in the allele frequencies were observed between 
those of African ancestry and other groups. Genotypes were in Hardy-Weinberg equilibrium at 
the p>0.05 level.  In the total cohort, there was no significant association between genotype and 
CHD risk under a recessive model examining the risk of T/T genotype relative to the combined 
C/T and C/C groups (OR=0.96 [95% CI 0.87-1.07]; Table 1).  Nor was there any evidence of 
association under an additive model (OR=1.00 [95% CI 0.96-1.05]; Table 1).  There was no 
evidence of heterogeneity in the odds ratios between ethnic groups.  Genotypes were available 
on 829 European Caucasian mothers of CHD cases (336 C/C, 396 C/T, and 97 T/T); there was 
no difference in genotype frequency between mothers of CHD cases and healthy controls (OR
for TT versus CT+CC =1.05 [95% CI 0.83-1.33]). 
Meta-analysis: 
The selection procedure resulting in the inclusion of 14 published case-control studies and 8 
published studies of mothers of CHD cases and controls in the final meta-analyses is described in 
Supplementary Table 1 online. The meta-analysis of case-control data incorporating the primary 
genotyping data from the present study included 7,697 cases and 13,159 controls, and the 
corresponding meta-analysis of data in mothers of cases and controls included 1,781 mothers of 
cases and 19,861 controls. 
The random-effects meta-analysis of offspring genotypes suggested association between
T/T genotype and CHD risk (summary OR=1.25 [95% CI 1.03-1.51], p=0.022; Figure 1) but 
moderate to high heterogeneity was present (I2=64.4%; p<0.0001 by Cochran’s Q).  The 
random-effects meta-analysis of maternal genotypes yielded no significant association of 
maternal T/T genotype with CHD risk (summary OR 1.13 [95% CI 0.87-1.47]; Figure 2) and low 
heterogeneity between these studies (I2=30.7%; p=0.163 by Cochran’s Q).  We considered 
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publication bias as a possible explanation for the high heterogeneity observed among the studies 
of offspring genotype; this seemed particularly important to explore as random-effects models 
can give undue weight to individuals in smaller studies, 18 and our subsidiary fixed-effect meta-
analysis of offspring genotypes showed no evidence of association (summary OR=1.06 [95% CI 
0.97-1.15]). A funnel plot of the studies contributing to the meta-analysis of offspring genotype 
was indeed highly suggestive of publication bias (Figure 3 left panel), and formal tests for 
publication bias were significant (Begg p=0.05; Egger p=0.03).  By contrast, there was no 
evidence of publication bias among the studies contributing to the meta-analysis of maternal 
genotype (Figure 3 right panel).  We used two statistical approaches to attempt to correct for
publication bias in the studies of offspring genotype.  The “trim and fill” method suggested 7 
missing studies, and the filled data yielded an estimated OR free of publication bias of 0.97 (95% 
CI 0.79-1.20).  This result was corroborated by the Copas selection model, which yielded an 
estimated OR free of publication bias of 1.00 (95% CI 0.84-1.20; Supplementary Figure 2).  
Finally, we followed the approach of previous investigators by designating studies in which the 
variance of the log OR was less than 0.05 as large. 19 Using these criteria identified three studies 
(the present EU-Caucasian and NY studies and the previous study of Xu et al 2010; these were 
also the only studies which included greater than 500 cases).  Among these studies, which 
included 83% of all CHD cases in the meta-analysis (6,416 of 7,697 cases), the summary OR 
was 0.97 (95% CI 0.91-1.03), with no evidence of heterogeneity (I2=0%; p-value by Cochran’s 
Q=0.6); while among the 13 smaller studies the OR was 1.62 (95% CI 1.19-2.21), further 
reinforcing the role of publication bias. 
We conducted analyses comparing the risk of CHD by C677T genotype in four 
diagnostic subgroups: septal defects (2723 cases and 5022 controls); conotruncal defects (1718  
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cases and 3168 controls); left sided lesions (389 cases and 717 controls); and other defects (623 
cases and 1149 controls; Figure 4).  In the “other defects” subgroup, the odds ratio for TT 
genotype was 0.68 (95% CI 0.49-0.95; p=0.021).  However, the 99% CIs we pre-specified to 
make allowance for multiple testing overlapped unity (99% CI 0.45-1.05); and adopting an 
alternative approach to multiple testing by applying a Bonferroni correction for four subgroup 
analyses likewise rendered that result non-significant (corrected p=0.084).  Moreover, a test for 
interaction was non-significant (F21=0.97; p=0.32) indicating no evidence of difference between 
the ORs in the different subgroups.  Finally, the “other defects” subgroup was of small size and 
hence the result in that subgroup might be particularly susceptible to the play of chance. 
Effect of prevailing level of folate intake: 
We grouped studies into low, medium and high folate groups with the intent of exploring any 
effect of prevailing folate levels on the risk of CHD associated with MTHFR genotype.
Although meta-regression including all studies suggested a borderline significant effect of
prevailing levels of plasma folate on the association, with a trend towards an increased OR in 
studies with lower folate (beta=0.33; p=0.02), there was marked heterogeneity among the low 
folate group of Asian studies largely responsible for the significant result (I2=89.3%), while there 
was no significant heterogeneity (I2=0%) in the high folate group of studies.  The low folate 
group included three small studies with extreme odds ratios (between 2.10 and 3.44) and one 
large study with a null result (OR 0.85), all conducted in China.  Therefore, publication bias 
appears to be confounded with region of study origin, and hence folate status, in our data.  In 
view of this we carried out a meta-regression restricted to the three large studies identified as 
above, which by chance represented each of the three folate status groups.  This analysis yielded
no relationship between folate status and CHD risk associated with MTHFR genotype  
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 (beta=0.078; p=0.49). 
Alternative genetic models:
Given the clear indication of publication bias in the dataset, we restricted analysis of alternative 
genetic models (C allele versus T allele; and C/C versus T/T genotype) to the three large studies 
only.  The allele model yielded an OR of 0.97 (95% CI 0.87-1.08) and comparison of T/T and 
C/C genotypes yielded an OR of 1.06 (95% CI 0.92-1.23).
Discussion
This is the largest study to date of genetic influences on CHD.  We analysed primary genotyping 
data on 5,814 CHD cases and 10,056 controls, together with meta-analysis of a further 1,883 
cases and 3,103 controls, and we found no significant effect of MTHFR C677T genotype on 
CHD risk.  Among the three largest studies, which contributed 83% of the genotyped cases, the 
confidence intervals were narrow around the null (OR=0.97 [95% CI 0.91-1.03]). In subgroup 
analyses, no effect of genotype was observed when we grouped CHD cases by the type of defect. 
Additionally, primary genotyping data on 829 mothers of CHD cases and 4,348 healthy controls, 
together with meta-analysis of a further 952 mothers of cases and 15,513 healthy controls, 
provided no support for an effect of maternal MTHFR genotype on CHD risk.  
Our analyses showed a substantial effect of publication bias that appeared to be 
confounded with study region of origin.  Consideration of large studies only yielded no evidence 
that MTHFR genotype had a differential effect on CHD risk dependent on prevailing levels of 
folate intake.  Since MTHFR genotype directly influences plasma folate levels, using the 
principles of “Mendelian randomization”, these data provide no support for the notion that 
plasma levels of folate influence CHD risk.
Four previous meta-analyses of this question had reached conflicting conclusions, with  
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early meta-analyses suggesting no effect of MTHFR genotype and more recent meta-analyses
suggesting the presence of an effect, possibly more marked in Caucasian populations 
(Supplementary Table 2). 20-23 The present study approximately trebles the number of cases 
investigated in published studies to date and conclusively rules out even a small effect of 
genotype on CHD risk.  Analyses using the principles of “Mendelian randomization” are 
typically limited by the power of the genetic instrument employed.  We therefore estimated the 
magnitude of the effect of MTHFR genotype on CHD risk that we were likely to have observed
if lower levels of plasma folate caused CHD, using previously published epidemiological data
(Supplementary Information). The upper 95% CI of 1.03 around our estimate robustly excludes 
an effect of the anticipated magnitude of ~18% and suggests that, among the populations we 
studied, any effect of plasma folate level on CHD risk is at most minimal. Moreover, we found 
no evidence of association between MTHFR genotype and being a mother of a case of CHD 
(such an association has been robustly demonstrated for neural tube defect, in keeping with a 
likely important contribution of maternal MTHFR genotype to fetal folate bioavailability during 
organogenesis);12, 14 our maternal genotype analyses approximately double the amount of 
information available on this question.   
Our study has certain limitations.  Although we attempted to exclude patients with 
recognized syndromes, not all such patients are diagnosed in childhood (for example, Noonan’s 
syndrome, the second most common syndromic cause of CHD after Down’s syndrome, may not 
infrequently be diagnosed in later life).  Inadvertent inclusion of such patients, who have specific 
genetic causes of their CHD, among our cases could have biased our results towards the null.  
However, it is unlikely that our sample contains significant numbers of undiagnosed Down’s 
syndrome patients, and the prevalence of other syndromes (e.g. Noonan’s: 1/1000-1/2500) is 
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insufficiently high to have materially affected our conclusions.  Our subgroup analyses were 
guided by diagnostic information and by the numbers of patients available in each subgroup.  We 
cannot exclude a role of the MTHFR gene in individual diagnostic categories which were too 
small to be analysed individually in our sample (eg Ebstein’s anomaly).  Since we did not 
preferentially ascertain multiplex families, we cannot comment on whether MTHFR genotype 
may act as a modifier in the presence of particular high-risk alleles responsible for highly 
familial CHD.  We focused on CHD conditions typically presenting in childhood; therefore, we 
have not addressed the relationship between MTHFR genotype and bicuspid aortic valve (BAV).  
Further studies focused on BAV, the commonest cardiovascular malformation, would be of 
interest.
Our results should not be interpreted as an argument against mandatory folate 
fortification, which substantially reduces the risk of NTD.  However, we found no evidence for a 
relationship between CHD and the MTHFR 677TT genotype, which is known to reduce plasma 
folate, in the largest genetic study of CHD thus far conducted.  More generally, our data adds to 
the results of previous investigations showing the substantial degree to which publication bias 
may influence the results of genetic meta-analyses.
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Table 1: MTHFR C677T polymorphism and risk of CHD in cases and controls genotyped in this study 
Population OR(95% CI)
T vs. C
OR(95% CI)
TT vs. CC+CT
CC
Cases
CT
Cases
TT
Cases
CC
Controls
CT
Controls
TT
Controls
Allele 
Frequencies
Cases
C              T
Allele
Frequencies 
Controls
C              T
EU-Caucasian 1.06 (0.98, 1.13) 1.00 (0.86, 1.16) 1244 1338 325 1885 1816 467 0.66       0.34 0.67       0.33
NY-Caucasian 0.94 (0.86, 1.03) 0.91 (0.76, 1.10) 676 716 196 1306 1474 428 0.65        0.35 0.64        0.36
NY-Black 0.90 (0.74, 1.10) 0.97 (0.51, 1.85) 508 132 14 992 293 29 0.88        0.12 0.87        0.13
NY-Hispanic 0.93 (0.79, 1.10) 0.97 (0.72, 1.31) 200 172 76 385 375 160 0.64         0.36 0.62         0.38
NY-other 0.91 (0.70, 1.20) 0.89 (0.47, 1.71) 131 72 14 258 156 32 0.77         0.23 0.75         0.25
Total 1.00 (0.96, 1.05) 0.96 (0.87, 1.07) 2759 2430 625 4826 4114 1116 0.68         0.32 0.69         0.31
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Figure Legends: 
Figure 1: Meta-analysis of offspring genotypes, random effects model.  The size of the grey 
square around the point estimate is proportional to the study size, and 95% confidence intervals 
for each study are shown.  The point estimate of the summary odds ratio is denoted by the 
broken red line, with 95% confidence interval denoted by a diamond. 
Figure 2: Meta-analysis of maternal genotypes, random effects model.  Conventions as in 
Figure 1.
Figure 3: Assessment of publication bias by funnel plots.  The left panel shows the funnel plot 
for the offspring genotype meta-analysis, and the right panel shows the funnel plot for the 
maternal genotype meta-analysis. Each study is represented by a dot, with the 95% pseudo-
confidence intervals shown as broken lines on either side of the summary odds ratio from the 
respective meta-analysis.  
Figure 4:  Meta-analysis of CHD diagnostic subgroups.  Patients from both the NY and EU-
Caucasian cohorts are included, grouped by diagnostic category of their dominant defect.  
Conventions as in Figure 1, other than 99%, rather than 95% confidence intervals are shown. 
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL METHODS 
 
Literature-based Meta-Analysis: 
We defined the inclusion criteria for studies as follows:  evaluation of the MTHFR C677T 
polymorphism and congenital heart disease; case-control study design; and sufficient data 
available either from publication or subsequent to contact with authors to calculate odds 
ratios and 95% confidence intervals.  We searched two scientific databases, PubMed 
(National Library of Medicine) and HuGE Navigator (v.1.4), and Google Scholar 
(scholar.google.com) using the search terms:  “methylene tetra-hydro-folate reductase 
(MTHFR)”; “heart defects, congenital”; “C677T”; “rs1801133”; “homocysteine”, “folate”, 
“folic acid”, alone or in combination, without restriction on language, with a cut-off date for 
publication of December 2011.  Where studies not in English were encountered, these 
were translated.  When eligible studies were identified, their bibliographies were hand-
searched for additional references.  Where genotype numbers could not be calculated 
from presented data, we made efforts to contact the authors for further information.  We 
restricted inclusion in the meta-analysis to published studies, and where the same dataset 
had been used in two or more publications, only the original paper was included.  The few 
previous studies that had used a family-based design in trios had used some variant of the 
transmission disequilibrium test (TDT), which tests for allelic rather than genotypic 
association.  The odds ratios under the recessive genetic model of principal interest to us 
(that is, the risk of T/T genotype relative to the other two genotypes C/T and C/C) cannot 
be calculated from the numbers of transmissions and non-transmissions that are typically 
reported when this method is used, therefore family-based studies were excluded.  Data 
on numbers of individuals participating were, however, extracted from these excluded 
studies.  For each study, two authors abstracted the first author’s surname, publication 
year, ethnicity of subjects, and frequencies for the three C677T genotypes in cases and 
controls, with discrepancies resolved by discussion.   
 
Since the effect of MTHFR genotype on plasma folate levels is dependent upon an 
individual’s folate status, and this could lead to heterogeneity in any effect of MTHFR 
C677T genotype on CHD risk in folate-replete and folate-deplete populations, we mapped 
the geographic origin of each study to flour fortification status and prevalence of folate 
deficiency using publicly available data from the Flour Fortification Initiative 
(http://www.sph.emory.edu/wheatflour) and World Health Organisation 
(http://www.who.int).  We stratified studies into three groups following the approach of 
Clarke et al., which was based upon consideration of plasma folate levels in 81 population-
based surveys including 200,000 individuals and took account of the introduction of folate 
fortification in the mid-1990s in many countries. 1 Studies conducted in countries practicing 
mandatory folate fortification and published following the introduction of fortification (chiefly 
US studies) were assigned to a high folate status group.  Our New York samples were 
from births that occurred prior mandatory fortification but were during the “ramp up phase” 
when fortification was voluntary. The result was that many US food manufacturers were 
supplementing early and our samples were therefore placed in the “high” group in these 
analyses. Studies conducted in those same countries pre-fortification were grouped 
together with those from Europe following the introduction of voluntary fortification in a mid 
folate status group.  Those conducted in Europe pre-fortification, and in Asian countries 
not practicing mandatory folate fortification (chiefly China) were assigned to a low folate 
status group. 
 
We identified 25 publications examining the relationship between MTHFR C677T and CHD 
(Supplementary Table 1). 2-26 Of these, three 11 5, 15 appeared to present substantially 
overlapping data and accordingly the largest and most recent dataset only 15 was used.  
TDT data only was presented in four studies which had enrolled families; 17 7 10, 21 as 
discussed above, these studies could not be analysed for the model of interest based on 
the summary data available and were excluded.  One study included both TDT and case-
control data; the case-control data was used in the pooled analyses.  One study 24 was 
concerned with the contribution of C677T to risk of CHD only in the setting of Down’s 
syndrome, and was therefore excluded. Despite attempts to communicate with authors, it 
was not possible to obtain case/control genotype numbers from one study, published in 
Chinese, which included 115 disease cases.  Of the studies remaining after the above 
exclusions, there were 14 in which comparison had been made between genotypes in 
cases of CHD and healthy controls, and there were 8 in which comparison had been made 
between genotypes in mothers of cases of CHD and healthy controls.  The flow chart 
summarising the selection process for the meta-analysis is presented in Supplementary 
Figure 1.  Among the 14 studies comparing case and control genotypes, four were 
conducted in China, five in Europe, three in North America, one in Brazil, and one in 
Taiwan.  These studies included a total of 1,883 cases and 3,103 controls.  Among the 8 
studies comparing genotypes between mothers of cases and controls, five were 
conducted in Europe, two in North America, and one in China.  These studies included a 
total of 952 mothers of cases and 15,513 controls.   
 
Estimation of power of genetic instrument for “Mendelian randomisation”: 
 
In the absence of data on plasma folate levels in our primary samples, we adopted an 
approach based on extrapolation from the effect sizes for the associations between 
MTHFR genotype and folate levels, and between differences in folate levels and CHD risk, 
observed in previously published epidemiological studies. Among 6793 participants in the 
NHANES cohort, Yang et al. showed that the T/T genotype was associated with an 
approximately 25% lower plasma folate level than the C/C genotype. 27 A recent analysis 
by Clarke et al. of 200,000 people in 81 population surveys of plasma folate levels, 
spanning the introduction of fortification in many countries in the mid-1990s, showed an 
approximately 50% increase in plasma folate following supplementation both in European 
and US/Australasian populations. 1 Finally, the Canadian time trend analysis of incident 
CHD conducted by Ionescu-Ittu et al. showed a 36% fall in CHD during the six years 
following the introduction of folate fortification. 28 Assuming a linear relationship between 
folate levels and a putative effect on CHD risk, from these three pieces of information we 
can calculate that the T/T genotype might be anticipated to confer about an 18% increase 
in CHD risk compared to the other two genotypes, through its effect on plasma folate 
levels, if the relationship between plasma folate and CHD were causal. Power calculations 
using this effect size, together with the observed allele frequencies at C677T in our cohort 
and the appropriate population prevalence of CHD, were performed using Genetic Power 
Calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/). 29  These indicated the study had 
>95% power to detect the anticipated effect under the recessive model (T/T versus C/T 
and C/C), and 80% power under the allelic association model.   
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First Author Country Year Year of enrolment Types of CHD 
Exclusion 
criteria 
Ethnicity of 
cases 
Ethnicity of 
controls CC CC- Mat TDT 
Folate  
status 
N cases/ 
N controls 
Wenstrom 2 USA 2001 1988–1998 All types 
Syndromes 
Teratogens  
DM 
Black 27% 
White 69% 
Other 4% 
Black 20% 
White 78% 
Other 2% 
Yes  - 
 
- High 26/116 
Junker 3 Germany 2001 1995–2000 All types except PFO Chromosomal  Caucasian Caucasian Yes 
 
- 
 
- Mid  114/228 
Storti 4 Italy 2003 2000–2001 Conotruncal (11 cases 22q11 del) Not described Caucasian Caucasian Yes Yes 
 
-  Mid 103/200 
Ying 5 China 2003 Unknown PDA, TOF, ASD,VSD, PS Not described Chinese Chinese Yes    - 
 
- - N/A 
Nurk 6 Norway 2004 1950–1952, 1967–1996 Unknown Not described Unknown Unknown 
 
- Yes - - - 
McBride 7 USA 2004 1998–2003 Left-sided CHD 
Multiple other 
malformation 
syndromes 
Caucasian 65% 
Hispanic 29% 
Black 5% 
Asian 1% 
Not 
described 
 
- 
 
- Yes - 
- 
Shaw 8 USA 2005 1987–1988 Conotruncal 
Aneusomies, 
single-gene 
disorders 
White 67% 
Hispanic 23% 
Other 10% 
White 58% 
Hispanic 
29% 
Other 13% 
Yes  - 
 
- High 
151/428 
 
Lee 9 
 
Taiwan 2005 2002–2003 All types Not described Asian Asian Yes  - 
 
- High 213/195 
 
Pereira 10 
 
Brazil 2005 Unknown All types Not described Unknown Unknown  - 
 
- Yes  - 
 
Liu 11 
 
China 2005 Unknown Conotruncal Not described Chinese Chinese     Yes 
 
- 
 
- Low 97/118 
 
Li Y 12 
 
China 2005 Unknown Unknown Not described Chinese Chinese Yes Yes  - - 
N/A 
 
Qiu XQ 13 
 
China 2006 Unknown Unknown Not described Chinese Chinese Yes Yes  - - 
N/A 
Van Beynum 
14 Netherlands 2006 2002–2003 All types 
NTD,  
Clefts, 
Syndromes 
Caucasian Caucasian, same area Yes Yes Yes Mid  
165/220 
Zhu 15 China 2006 Unknown ASD, PDA 
DM, PKU, 
Teratogens 
X-ray 
Asian, province 
in China 
Asian, same 
area Yes Yes 
 
- Low  
56/103 
Hobbs 16 USA 2006 1998–2004 
Septal, 
Conotruncal, 
right-left sided CHD 
Syndromes 
Chromosomal White White 
 
- Yes 
 
- - 
- 
Supplemental Table 1 : Studies investigating association between MTHFR C677T and CHD identified by literature search 
 
  
First Author Country Year  Year of inclusion Types of CHD Exclusion criteria 
Ethnicity of 
cases 
Ethnicity of 
controls CC  CC- Mat TDT 
Folate 
status 
N cases/ 
N controls 
Hobbs 17 USA 2006 1998–2004 
Septal 
Conotruncal, 
right-left sided CHD 
Syndromes, 
Chromosomal Not described Not described       - – Yes - 
 
- 
Galdieri18  Brazil 2007 Unknown Unknown Syndromes, Multiple malf. 
White 22% 
Non-White 78% 
White 53% 
Non-White 
47% 
Yes Yes – High 
 
58/38 
Wintner 19 Austria 2007 1993-2004 All types 
Aneuploidies 
Syndromes 
Maternal DM 
Teratogens 
Caucasian Caucasian        - Yes - - 
 
- 
Van Driel 20 Netherlands 2008 Unknown Multiple types Not described 
Dutch natives 
89% 
European others 
11% 
Dutch natives 
89% 
European 
others 11% 
Yes Yes - Mid 
 
229/251 
Goldmuntz 21 USA 2008 1997-2007 Conotruncal Syndromes Chromosomal 
Any racial/ethnic 
group 
Any 
racial/ethnic 
group 
- - Yes - 
 
- 
 
Marinho 22 Portugal 2009 Unknown TOF Not described White Unknown Yes - - Mid  38/251 
 
Li D 23 
 
China 2009 Unknown Unknown Not described Chinese Chinese Yes    - - Low  
 
104/208 
Brandalize 24 Brazil 2009 Unknown CHD in trisomy 21 
Other syndrome 
Other offspring 
with another 
syndrome 
90% European 
descent 
6.4% African 
descent 
3.4% other 
93.8% 
European 
descent 
4.8% African 
descent 
1.4% other 
- Yes - - 
 
 
- 
Garcia-
Fragoso 25 Puerto-Rico 2010 Unknown Multiple 
Chromosomal, 
Syndromes, 
PDA associated 
with prematurity, 
Antiepileptics, 
conditions 
associated with 
food intolerance, 
malabsorption, or 
wasting 
syndromes,  
maternal DM 
White 76% 
Black 7% 
Other 17% 
White 76% 
Black 7% 
Other 17% 
Yes Yes - High  
 
 
 
 
 
27/220 
Xu J 26  China 2010 2006-2008 
Left-sided CHD, 
Septal, PDA, 
Cyanotic 
 
Chromosomal, 
Family history 
Maternal DM, 
PKU 
Teratogens 
Maternal drugs 
 
Chinese Chinese Yes - - Low 
 
 
 
502/527 
CC: case-control study involving genotype frequency comparison in affected people and controls 
CC-Mat: case-control study involving genotype frequency comparison in mothers of affected people and controls 
TDT: study involving the examination of genotype transmission in families, typically using a variant of the “transmission disequilibrium test” 
22q11del:  Chromosome 22q11 deletion syndrome (also known as DiGeorge/velocardiofacial/CATCH-22 syndromes) 
ASD: atrial septal defect  
DM: diabetes mellitus 
NA: not applicable 
PDA: persistent ductus arteriosus 
PFO: patent foramen ovale 
PKU: phenylketonuria 
PS: pulmonary stenosis 
TOF: tetralogy of Fallot 
VSD, Ventricular septal defect 
 
  
Supplementary Table 2:  Previous meta-analyses of MTHFR C677T association with CHD 
 
  
 
Meta-analysis, by first 
author name and year 
 
 
 
Number 
of studies 
 
OR [95% CI] 
 
 
 
Number of 
cases/controls 
 
 
 
Model 
 
 
 
 
Van Beynum, 200730 
 
 
8 
 
1.3 [0.97–1.73] 
 
882/1511 
 
TT vs. CC 
 
 
Verkleij-Hagoort, 200731 
 
 
6 
 
1.14 [0.86–1.53] 
 
774/1393 
 
TT+CT vs. CC 
 
Nie et al, 2011 32 
 
 
13 
 
1.27 [0.98-1.66] ALL 
1.45 [1.08-1.95] Caucasian 
 
 
1898/3003 
 
TT vs. CC+CT 
 
Yin et al, 2012 33 
 
 
13 
 
1.55 [1.25, 1.93] 
 
1655/2327 
 
TT vs. CC 
Supplemental Figure 1: PRISMA flow diagram for case-control meta-analysis 
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Supplemental Figure 2:  Copas’ selection model plot.  The upper panel shows the p-
value for residual selection bias (on y-axis) at diminishing probability of publication, 
indicating that this crosses a threshold of 0.1 at a probability of publication of ~0.7.  The 
right panel shows the corresponding odds ratios and 95% CIs for the association of T/T 
genotype with CHD risk at diminishing probability of publication.   
 
 
